A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic asthma.
JSP-CP-012
Phase 1 other active
Quick answer
A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic asthma. for allergic asthma is a Phase 1 program (other) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jasper Therapeutics
- Indication
- allergic asthma
- Phase
- Phase 1
- Modality
- other
- Status
- active